Most cited papers from Alkermes (United States)

Alkermes (United States)

What are the most cited papers from Alkermes (United States)?

The most cited paper from Alkermes (United States) is "Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress" (Carl P. LeBel, Harry Ischiropoulos, Stephen Claude Bondy, 1992), with 2,706 citations. Next come "On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis" (832) and "Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence" (635).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 121 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress Carl P. LeBel, Harry Ischiropoulos, Stephen Claude Bondy · Chemical Research in Toxicology Open access	Mar 1992	2,706
2	On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis Raymond T. Bartus · Experimental Neurology	Jun 2000	832
3	Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence James C. Garbutt, Henry R. Kranzler, Stephanie S. O’Malley et al. · JAMA	6 Apr 2005	635
4	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial Evgeny M. Krupitsky, Edward V. Nunes, Walter W Ling et al. · The Lancet	Apr 2011	559
5	Trojan particles: Large porous carriers of nanoparticles for drug delivery Nicolas Tsapis, Derrick Bennett, Brian E. Jackson et al. · Proceedings of the National Academy of Sciences Open access	28 Aug 2002	542
6	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia Adriana E. Tron et al. · Nature Communications Open access	11 Dec 2018	496
7	Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody Emilio A. Emini, William A. Schleif, Jack H. Nunberg et al. · Nature	Feb 1992	476
8	Improving protein therapeutics with sustained-release formulations Scott D. Putney, Paul A. Burke · Nature Biotechnology	Feb 1998	460
9	The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization Lewis D. Pennington, Demetri T. Moustakas · Journal of Medicinal Chemistry Open access	8 Feb 2017	415
10	Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Phillip M. Friden, Lee R. Walus, Gary F. Musso et al. · Proceedings of the National Academy of Sciences Open access	Jun 1991	412
11	Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro Michael L. Tracy · Biomaterials	Jun 1999	412
12	Multiple-micronutrient supplementation for women during pregnancy Emily Catherine Keats, Batool Azra Haider, Emily W.Y. Tam et al. · Cochrane Database of Systematic Reviews Open access	15 Mar 2019	383
13	Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth GEORGE E. WOODY, Sabrina A. Poole, Geetha Subramaniam et al. · JAMA Open access	4 Nov 2008	360
14	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses Keiro Ikeda, Tomotsugu Ichikawa, Hiroaki Wakimoto et al. · Nature Medicine	Aug 1999	342
15	Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial Suzanne Craft, Amy Claxton, Laura D. Baker et al. · Journal of Alzheimer s Disease Open access	29 Mar 2017	339
16	Blood-Brain Barrier Penetration and in Vivo Activity of an NGF Conjugate Phillip M. Friden, Lee R. Walus, Patricia M. Watson et al. · Science	15 Jan 1993	326
17	Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease Dwaine F. Emerich, Shelley R. Winn, Philippe Hantraye et al. · Nature	Mar 1997	325
18	A month–long effect from a single injection of microencapsulated human growth hormone Olufunmi L. Johnson, Jeffrey L. Cleland, Hyejung Lee et al. · Nature Medicine	Jul 1996	294
19	The impact of genetic modification of human foods in the 21st century Stella G. Uzogara · Biotechnology Advances	May 2000	268
20	Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes Mary Beth DeYoung, Leigh MacConell, Viren Sarin et al. · Diabetes Technology & Therapeutics Open access	13 Jul 2011	242
21	Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Kathryn E. Saatman, H. Murai, Raymond T. Bartus et al. · Proceedings of the National Academy of Sciences Open access	16 Apr 1996	226
22	Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Raymond T. Bartus, Neil J. Hayward, Peter J. Elliott et al. · Stroke	Nov 1994	219
23	The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres Olufunmi L. Johnson, Warren Jaworowicz, Jeffrey L. Cleland et al. · Pharmaceutical Research	Jun 1997	218
24	An Essential Yeast Gene Encoding a Homolog of Ubiquitin-activating Enzyme R. Jürgen Dohmen, Reiner Stappen, John P. McGrath et al. · Journal of Biological Chemistry Open access	Jul 1995	210
25	A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma Michael D. Prados, S. Clifford Schold, Howard Alan Fine et al. · Neuro-Oncology Open access	Apr 2003	205
26	Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia Gabriel E. Kaplan, Júlio Casoy, Jacqueline Zummo · Patient Preference and Adherence Open access	Nov 2013	200
27	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches Marta Peciña, Jordan F. Karp, Sanjay J. Mathew et al. · Molecular Psychiatry Open access	28 Jun 2018	193
28	The Effect of Formulation Excipients on Protein Stability and Aerosol Performance of Spray-Dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody1 James D. Andya, Yuh‐Fun Maa, Henry R. Costantino et al. · Pharmaceutical Research	Mar 1999	190
29	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds Franco Lombardo, Giuliano Berellini, Ronald Scott Obach · Drug Metabolism and Disposition Open access	16 Aug 2018	186
30	Protein Spray-Freeze Drying. Effect of Atomization Conditions on Particle Size and Stability Henry R. Costantino, Laleh Firouzabadian, Ken Hogeland et al. · Pharmaceutical Research	Nov 2000	184
31	Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein Karen G. Carrasquillo, Ann M Stanley, Juan C Aponte-Carro et al. · Journal of Controlled Release	Oct 2001	181
32	Evaluation of Opioid Modulation in Major Depressive Disorder Elliot W. Ehrich, Ryan Z. Turncliff, Yangchun Du et al. · Neuropsychopharmacology Open access	18 Dec 2014	176
33	Enhanced Tumor Uptake of Carboplatin and Survival in Glioma-bearing Rats by Intracarotid Infusion of Bradykinin Analog, RMP-7 Koichiro Matsukado, Takanori Inamura, Shin Nakano et al. · Neurosurgery	Jul 1996	176
34	The Role of Leukocytes Following Cerebral Ischemia: Pathogenic Variable or Bystander Reaction to Emerging Infarct? Dwaine F. Emerich, Reginald L. Dean, Raymond T. Bartus · Experimental Neurology	2002	175
35	Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers Caroline Pérez, Ingrid J. Castellanos, Henry R. Costantino et al. · Journal of Pharmacy and Pharmacology Open access	Mar 2002	174
36	The relationship between excitotoxicity and oxidative stress in the central nervous system Stephen Claude Bondy, Carl P. LeBel · Free Radical Biology and Medicine Open access	Jun 1993	167
37	In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development Franco Lombardo, Prashant V. Desai, Rieko Arimoto et al. · Journal of Medicinal Chemistry	13 Jun 2017	156
38	Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium Richard D. Broadwell, Belinda Baker-Cairns, Phillip M. Friden et al. · Experimental Neurology	Nov 1996	149
39	The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review Leona Bessonova, Kristine Ogden, Michael J. Doane et al. · ClinicoEconomics and Outcomes Research ReviewOpen access	Sep 2020	144
40	Rational design of a new antibiotic class for drug-resistant infections Thomas F. Durand-Réville et al. · Nature	15 Sep 2021	142
41	Systemic Administration of a Nerve Growth Factor Conjugate Reverses Age-Related Cognitive Dysfunction and Prevents Cholinergic Neuron Atrophy Cristina M. Bäckman, Gregory M. Rose, Barry J. Hoffer et al. · Journal of Neuroscience Open access	Sep 1996	142
42	ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy Jared E. Lopes, Jan L. Fisher, Heather L. Flick et al. · Journal for ImmunoTherapy of Cancer Open access	Apr 2020	141
43	Reduction in heavy drinking as a treatment outcome in alcohol dependence David R. Gastfriend, James C. Garbutt, Helen M. Pettinati et al. · Journal of Substance Abuse Treatment	23 Feb 2007	140
44	Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement James A. Bolognese, Thomas J. Schnitzer, Elliot W. Ehrich · Osteoarthritis and Cartilage Open access	30 Jun 2003	140
45	Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7 E. Ya. Sanovich, Raymond T. Bartus, Phillip M. Friden et al. · Brain Research	Dec 1995	140
46	Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development1This manuscript is dedicated to the memory of Dr. Michael J. Cronin. Dr. Cronin was a brilliant endocrine scientist with an incredible ability to objectively evaluate any problem, no matter how complex. His spirit and knowledge contributed to the success of the work described herein and his wisdom co Jeffrey L. Cleland, Olufunmi L. Johnson, Scott D. Putney et al. · Advanced Drug Delivery Reviews Review	Oct 1997	139
47	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study The EVOLVE-MS-2 Study Group, Robert T. Naismith, Annette Wundes et al. · CNS Drugs Open access	17 Jan 2020	136
48	Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7 Raymond T. Bartus, Peter J. Elliott, Reginald L. Dean et al. · Experimental Neurology	Nov 1996	136
49	Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing Mark S. Fineman, Shawn D. Flanagan, Kristin Taylor et al. · Clinical Pharmacokinetics	2 Dec 2010	135
50	Predicting extrathoracic deposition from dry powder inhalers Wesley H. DeHaan, Warren H. Finlay · Journal of Aerosol Science	7 Nov 2003	134

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.